Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of April 2019. The filing, dated April 10, 2019, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. The filing references the company's active Registration Statements on Forms F-3 and S-8.
Financial Metrics
The provided filing text does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document. The filing acts solely as a conduit for the attached press release and does not include a financial statement or performance summary.
Material Changes
The filing text does not provide details regarding material changes versus prior periods. The content is limited to the administrative incorporation of a press release and regulatory signatures. Specific operational or financial changes described in the press release are not included in the source text provided.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. The document references a press release (Exhibit 99.1) which likely contains such information, but the text of that release is not present in the input data.
Key Facts for Investor Verification
- The registrant is Galapagos NV, not Lakefront Biotherapeutics NV (as noted in the request metadata).
- The filing date is April 10, 2019.
- The primary content is a press release attached as Exhibit 99.1, which is not included in the provided text.
- Investors must review the full text of Exhibit 99.1 to understand the specific event or announcement triggering this filing.
- The filing incorporates information into active registration statements (File No. 333-230639 and various S-8 filings).